Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron in Ventricular Arrhythmia
NCT07566208Phase 2Not yet recruiting
- Sponsor
- Cedars-Sinai Medical Center
- Start
- May 2026
- Primary completion
- May 2028
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of mirabegron in ventricular tachycardia (VT), sponsored by Cedars-Sinai Medical Center. Primary endpoint: Burden of Ventricular Tachycardia at 3 months. Planned start May 2026; status: not yet recruiting.
02
Drugs
mirabegron
03
Conditions
ventricular tachycardia (VT)
Beyond the preview
Go deeper on NCT07566208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07566208.